Erasca announces strategic in-licensing of RAS-targeting franchise

Erasca “announced it has entered into exclusive license agreements for two preclinical RAS programs-a potential best-in-class pan-RAS molecular glue, ERAS-0015, and a potential first-in-class pan-KRAS inhibitor, ERAS-4001, and provided a pipeline update. ERAS-0015 and ERAS-4001 are highly potent, orally bioavailable molecules with complementary RAS inhibitory mechanisms that have the potential to address unmet needs in nearly 2.7 million patients who are diagnosed annually globally with RAS-mutant tumors, of which over 2.2 million patients are diagnosed with KRAS-mutant tumors.”